Sun Pharma Share Price (SUNPHARMA)
Check the latest share price of Sun Pharma, along with the price target, peer comparison, quarterly results, recent news, expert analysis, shareholding pattern, and other key fundamentals to make informed investment decisions.
as on 04:01PM, 09 Jul 2025
NSE
Sun Pharma Stock Performance
Get live Sun Pharma share price, day's high and low, historical returns, and market stats.
Day's Low
Day's High
₹1,647Day's Price Range₹1,680.852 Week's Low
52 Week's High
₹1,549.852-Week Price Range₹1,960.35
| Returns % | |
| 1 Month Return | -1.29 % |
| 3 Month Return | + 1.23 % |
| 1 Year Return | + 5.49 % |
| 3 Year Return | + 95.1 % |
| 5 Year Return | + 247.03 % |
| Market Stats | |
| Previous Close | ₹1,672.50 |
| Open | ₹1,660.00 |
| Volume | 21.79L |
| Upper Circuit | ₹1,839.70 |
| Lower Circuit | ₹1,505.30 |
Sun Pharma Fundamentals & Key Indicators
Check Sun Pharma market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
₹4,01,288.77 Cr
Return on Equity (ROE)
17.83
PE Ratio (TTM)
36.68
Return on capital employed (ROCE)
16.29
Industry PE ratio
52.61
Beta (LTM)
0.59
P/B Ratio
16.41
Dividend Yield
0.83
PEG Ratio
6.43
Quarterly Earnings Growth YOY
-18.97
EPS (TTM)
45.76
Sector
Pharmaceuticals
Book Value
301
Technical Analysis
Bearish
View Technical Analysis
How to invest in Sun Pharma?
Investing in Sun Pharma is simple. You can open a free INDstocks investment account on the INDmoney App. Search for Sun Pharma or SUNPHARMA on the app to check live prices of the stock and click on Buy or SIP. You can invest by selecting the number of shares or set up a fixed SIP to invest every month or week.
For example: You can buy 10 shares of Sun Pharma or start an SIP based on the market price on each investment date.
You can easily transfer money to your stock account via the INDmoney app and start investing in stocks like Sun Pharma with just a few clicks!
Sun Pharma Stock's Interest Amongst Investors
Sun Pharma Valuation
Track how Sun Pharma P/E has moved over time to understand its valuation trends.
Sun Pharma in the last 5 years
Lowest (19.47x)
March 23, 2020
Today (36.68x)
July 8, 2025
Industry (52.61x)
July 8, 2025
Highest (184.63x)
August 28, 2020
Today’s Price to Earnings Ratio: 36.68x
Sun Pharma Stock Recommendation
Get updated buy, sell, and hold recommendations by analysts on Sun Pharma.
based on 36 analysts
80.56%
Buy
11.11%
Hold
8.33%
Sell
80.56% of analysts recommend a 'BUY' rating for Sun Pharma. Average target price of ₹1981.44
Source: S&P Global Market Intelligence
Sun Pharma Share Price Target
Get share price movements and forecasts by analysts on Sun Pharma.
Sun Pharma price forecast by 36 analysts
Upside of18.47%
High
₹2450
Target
₹1981.44
Low
₹1475
Sun Pharma target price ₹1981.44, a slight upside of 18.47% compared to current price of ₹1669.4. According to 36 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Sun Pharma revenue growth forecast
Expected growth rate Q1, FY2027:29.83%
Forecast
Actual
Including amortisation and stock based compensations
Sun Pharma EPS growth forecast
EPS estimate Q1, FY2027:49.81%
Forecast
Actual
Source: S&P Global Market Intelligence
Sun Pharma Financial Results
Get the annual and quarterly financial summary of Sun Pharma, including revenue, profit, loss and more.
Indices Featuring Sun Pharma Stock
Check stock indices that include Sun Pharma.
Sun Pharma Earnings and Dividends
View detailed summary of the earnings and dividend history of Sun Pharma.
Sun Pharmaceutical Industries Ltd Earnings Results
Sun Pharmaceutical Industries Ltd’s net profit fell -19.01% since last year same period to ₹2,149.88Cr in the Q4 2024-2025. On a quarterly growth basis, Sun Pharmaceutical Industries Ltd has generated -25.95% fall in its net profits since last 3-months.
Read More about Earnings ResultsSun Pharmaceutical Industries Ltd Dividends May,2025
In the quarter ending March 2025, Sun Pharmaceutical Industries Ltd has declared dividend of ₹5.50 - translating a dividend yield of 1.25%.
Read More about Dividends
Sun Pharma Shareholding Pattern
View the shareholding pattern breakup of promoters, FIIs, DIIs, and retail investors in Sun Pharma.
| Investors | Holdings % | Quarterly Trend | 3M change |
|---|---|---|---|
| Promoter Holdings | 54.48% | 0.00 | |
| Foreign Institutions | 17.96% | 0.00 | |
| Mutual Funds | 12.21% | 0.00 | |
| Retail Investors | 8.87% | 0.00 | |
| Others | 6.48% | 0.00 |
Sun Pharma vs Peers
Compare market cap, revenue, PE, and other key metrics of Sun Pharma with its industry peers.
Company | Analyst View | Market Cap(in ₹ Cr) | 5 Year CAGR | Debt to Asset Ratio | Net Profit(in ₹ Cr) | Yearly Revenue(in ₹ Cr) |
|---|---|---|---|---|---|---|
| BUY | 4,01,288.77 | 49.41% | 0.68 | 10,980 | 52,578 | |
| HOLD | 1,84,182.10 | 43.76% | 0.50 | 1,600 | 7,845 | |
| BUY | 1,12,440.06 | 36.23% | 0.67 | 1,911 | 11,516 | |
| BUY | 49,380.75 | -1.8% | 0.58 | 1,297 | 14,755 | |
| HOLD | 31,110.95 | 0.76% | 0.50 | 772 | 5,664 |
Sun Pharma News & Key Events
Latest news and events in one place to help you make informed investing decisions in Sun Pharma.
Sun Pharma Enhances Compliance and Focuses on Specialty Growth - 08 Jul, 2025
Sun Pharmaceutical Industries is addressing USFDA compliance issues at three facilities while investing in Specialty products. The company reported a 9% revenue growth in FY25, with strong performance in Specialty sales.Sun Pharma Proposes Dividend Amid Regulatory Efforts - 07 Jul, 2025
Sun Pharmaceutical Industries proposes a final dividend of Rs 5.50 per share for FY25. The company is also addressing USFDA compliance issues at three facilities, anticipating mid to high single-digit growth in FY26.Sun Pharma Faces Pricing Pressures Amid New Study - 04 Jul, 2025
Sun Pharmaceutical Industries is experiencing pricing pressures while announcing a clinical study for tildrakizumab, a potential treatment for genital psoriasis, which could enhance its dermatology portfolio.Sun Pharma Addresses Misleading Vaccine Claims - 03 Jul, 2025
Sun Pharma's Chairman Dilip Shanghvi expressed concern over the deaths of young individuals in Karnataka, emphasizing that linking these to the COVID-19 vaccine is misleading and unsupported by scientific evidence.Sun Pharma Advances Phase 3 Study on Tildrakizumab - 02 Jul, 2025
Sun Pharmaceutical Industries Limited announced a Phase 3 clinical study for tildrakizumab, targeting moderate to severe genital psoriasis. The study's outcomes could significantly influence investor confidence and market dynamics in the dermatological sector.Sun Pharma Shows Bullish Potential with Key Support - 30 Jun, 2025
Sun Pharma's stock is showing bullish potential with a target price of ₹1,840 and a key support zone between ₹1,640 and ₹1,650. A hidden bullish divergence on the daily RSI suggests a continuation of the uptrend, despite recent consolidation. Investors are advised to go long in the ₹1,690–₹1,670 range, with a stop loss below ₹1,600.Delhi Drug Control Uncovers Fake Cholesterol Medicines - 28 Jun, 2025
The Delhi drugs control department has exposed a distribution network selling counterfeit Rosuvas F 20 tablets, following a complaint from Sun Pharmaceutical Industries Ltd. This incident raises concerns about drug safety and authenticity.Sun Pharma Faces Setback with Nidlegy Withdrawal - 25 Jun, 2025
Philogen, Sun Pharma's partner, withdrew the EU application for Nidlegy due to data issues. The company also scheduled an investor meeting in Mumbai.Sun Pharma Advances Studies on Key Treatments - 24 Jun, 2025
Sun Pharmaceutical Industries Limited announced significant updates on two studies: Tildrakizumab for Psoriatic Arthritis and Sonidegib's long-term safety, potentially enhancing investor confidence and market position.Counterfeit Drugs Linked to Sun Pharma Seized - 20 Jun, 2025
Authorities seized counterfeit cholesterol drugs worth ₹3 lakh, falsely marketed as products of Sun Pharmaceutical Industries Limited, which confirmed the stocks were not genuine.Sun Pharma Faces Pressure Amid Regulatory Concerns - 17 Jun, 2025
Sun Pharmaceutical Industries Ltd experienced a decline in share price due to concerns over the Halol facility's regulatory issues. Nomura's Neutral rating reflects limited upside potential, with shares falling over 2% on June 17, 2025, making it the biggest loser on the Sensex.Sun Pharma Faces FDA Scrutiny, Leadership Change Announced - 14 Jun, 2025
Sun Pharmaceutical Industries faces renewed scrutiny from the US FDA with eight observations from a recent inspection. The company also announced Kirti Ganorkar as the new Managing Director, succeeding Dilip Shanghvi. Additionally, Sun Pharma reported a 19% decline in net profit for Q4 FY25, despite an increase in revenue.Sun Pharma Announces Leadership Transition with Ganorkar - 13 Jun, 2025
Sun Pharmaceutical Industries Ltd has appointed Kirti Ganorkar as Managing Director, effective September 1, 2025, as part of a structured succession plan. Founder Dilip Shanghvi will remain as Executive Chairman, focusing on the specialty portfolio. The leadership changes also include a new CEO for North America, Richard Ascroft, succeeding Abhay Gandhi.Sun Pharma Breaks Resistance, Positive Outlook - 12 Jun, 2025
Sun Pharmaceutical Industries has broken above its recent consolidation, trading higher at ₹1,715. The stock surpassed the crucial 200-day EMA resistance at ₹1,710, with a positive RSI indication, suggesting a bullish trend.
Insights on Sun Pharmaceutical Industries Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTPrice Rise
In the last 3 months, SUNPHARMA stock has moved up by 1.2%
NO EFFECTAgainst Peers
In the last 3 years, Torrent Pharmaceuticals Ltd has given 123.9% return, outperforming this stock by 28.8%
- NO EFFECT
Promoter Holding Unchanged
Promoters holdings remained unchanged at 54.48% of holdings in Mar 2025 quarter
- NO EFFECT
Against Peers
In the last 1 year, Divis Laboratories Ltd has given 52.4% return, outperforming this stock by 46.9%
NEGATIVE IMPACTRevenue Fall
Revenue is down for the last 2 quarters, 14.14K Cr → 13.57K Cr (in ₹), with an average decrease of 4.0% per quarter
- NEGATIVE IMPACT
FII Holding Down
Foreign Institutions have decreased holdings from 18.05% to 17.96% in Mar 2025 quarter
- NEGATIVE IMPACT
Retail Holding Down
Retail Investor have decreased holdings from 8.92% to 8.87% in Mar 2025 quarter
- NEGATIVE IMPACT
Profit Down
Netprofit is down for the last 3 quarters, 3.04K Cr → 2.14K Cr (in ₹), with an average decrease of 15.2% per quarter
- NEGATIVE IMPACT
MF Holding Down
Mutual Funds have decreased holdings from 12.24% to 12.21% in Mar 2025 quarter
About Sun Pharma
Sun Pharma's branded formulations include products for cardiovascular, central nervous system, gastroenterology, ophthalmology, and dermatology. Sun Pharma's specialty generics include injectables, inhalants, and complex products. Sun Pharma's API portfolio includes products for a range of therapeutic areas, including cardiovascular, central nervous system, gastroenterology, and dermatology.
Sun Pharma's top products include Modalert, a generic version of Modafinil for treating sleep disorders; Glocip, a generic version of Glipizide for treating diabetes; and Doxicip, a generic version of Doxycycline for treating bacterial infections. Sun Pharma's popular brands include Revital, a multivitamin supplement; Tazret, a topical retinoid for treating psoriasis; and Olmecip, a generic version of Olmesartan for treating hypertension.
Revenue: ₹12,815.58Cr as on March 2025 (Q4 FY25)
Net Profit: ₹2,160.64Cr as on March 2025 (Q4 FY25)
Listing date: 08 Feb, 1995
| Organisation | Sun Pharmaceutical Industries Ltd |
| Headquarters | Mumbai |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
Mutual Funds that own Sun Pharma
Check out the Mutual Funds with significant holdings in Sun Pharma.
FAQs
What is Sun Pharma share price today?
Sun Pharma share price today stands at ₹1669.4, Open: ₹1660, Previous Close: ₹1672.5, High: ₹1680.8, Low: ₹1647, 52 Week High: ₹1960.35, 52 Week Low: ₹1549.8.
What is today's traded volume of Sun Pharma?
Today's traded volume of Sun Pharma is 21.79L. Which means that 21.79L shares of Sun Pharma were bought and sold on the stock market during today's trading session.
What is Sun Pharma's market cap today?
Today's market capitalisation of Sun Pharma is ₹4,01,288.77 Cr. Market cap or market capitalisation is the total value of a company’s outstanding shares in the stock market, calculated by multiplying the current share price by the total number of shares issued by the company.
What is the 52 week high and 52 week low range of Sun Pharma?
Sun Pharma’s 52 week high is ₹1960.35 and 52 week low is ₹1549.8. The current share price of Sun Pharma is ₹1669.4, which is -14.84% down from its 52 week high and 7.72% up from its 52 week low.